The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,922,080 in first-year total cost, median $385,444.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BMCT-C (01)]2
- Cancer Genetics Study Section[CG]1
- Cancer Molecular Pathobiology Study Section[CAMP]1
- Special Emphasis Panel[ZRG1 OBT-D (02)]1
Most frequent institutions
- UNIVERSITY OF IOWA2
- MASSACHUSETTS GENERAL HOSPITAL1
- TULANE UNIVERSITY OF LOUISIANA1
- UNIVERSITY OF MICHIGAN AT ANN ARBOR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex1R01CA237031-01A1 | TANAS, MUNIR | UNIVERSITY OF IOWA, IA | $348,201 | CG |
| 2019 | An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT1R01CA222856-01A1 | LEE, SEAN B. | TULANE UNIVERSITY OF LOUISIANA, LA | $358,185 | ZRG1 |
| 2018 | Investigations of menin function in Ewing sarcoma1R01CA218116-01A1 | LAWLOR, ELIZABETH R | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $442,743 | CAMP |
| 2018 | Gene expression signature based screening in Ewing sarcoma1R37CA217910-01A1 | GORDON, DAVID J | UNIVERSITY OF IOWA, IA | $387,507 | ZRG1 |
| 2018 | New models and therapeutic approaches in alveolar rhabdomyosarcoma1R01CA226926-01 | LANGENAU, DAVID MICHAEL | MASSACHUSETTS GENERAL HOSPITAL, MA | $385,444 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.